ToolGen

199800· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩43,400+8.36%

2026-08-04

Financials

Valuation Metrics

ToolGen's Market Cap is ₩3905B. At end of 2025 it was ₩5273B. Ranked #521 of 2,436 in KR market (top 21%), #200 of 1,649 on KOSDAQ (top 12%), #60 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 26%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	390.50B KRW	KR#521/2,436 Sec#60/234
Revenue	1.57B KRW	KR#2,388/2,436 Sec#217/234
Net Income	-36.73B KRW	KR—/2,436 Sec—/234
Total Assets	57.28B KRW	KR#2,119/2,436 Sec#187/234
Net Assets	53.17B KRW	KR#1,833/2,436 Sec#155/234
Employees	82	KR#1,777/2,436 Sec#145/234
Value
P/B	7.34x	KR#2,303/2,436 Sec#198/234
P/S	249.04x	KR#2,402/2,436 Sec#219/234
FCF Yield	-5.29%	KR—/2,436 Sec—/234
Profitability
ROE	-69.09%	KR#2,306/2,436 Sec#211/234
ROA	-64.13%	KR#2,369/2,436 Sec#223/234
Op. Margin	-1484.50%	KR#2,392/2,436 Sec#220/234
Revenue Growth	202.56%	KR#66/2,436 Sec#12/234
Earnings Growth	-689.94%	KR#1,663/2,436 Sec#113/234
Financial Health
Debt Ratio	107.74%	KR#390/2,436 Sec#56/234
Total Debt	0 KRW	KR—/2,436 Sec—/234
FCF	-20.67B KRW	KR#1,904/2,436 Sec#181/234
Cash	5.70B KRW	KR#1,937/2,436 Sec#171/234
Current Ratio	10.94x	KR#86/2,436 Sec#23/234
Performance
1Y Return	58.39%	KR#204/2,436 Sec#18/234
1M Return	20.06%	KR#124/2,436 Sec#7/234
From 52W High	-69.44%	KR#2,116/2,436 Sec#189/234
1Y MDD	-75.18%	KR#2,149/2,436 Sec#192/234
Trading
Volume	31,668 shares	KR#1,622/2,436 Sec#159/234
Foreign Own.	1.23%	KR—/2,436 Sec—/234
Per Share
EPS	-4,189 KRW	KR—/2,436 Sec—/234
BPS	5,914 KRW	KR#1,315/2,436 Sec#95/234

Company Info

CEO 유종상

Employees 82

Founded 1999

HQ 서울특별시 강서구, KR

Website toolgen.com

동사는 1999년 유전자 교정 플랫폼 사업을 위해 설립되어 2021년 코스닥 시장에 상장함. ZFN, TALEN, CRISPR/Cas9 등 유전자가위를 독자 개발한 세계 유일 기업으로 CRISPR 유전자가위의 진핵세포 작동을 세계 최초로 입증한 특허 보유, 특허 388건 확보함. 유전자 교정 플랫폼 기술의 원천특허 기반으로 특허 수익화, 치료제 및 종자 관련 연구개발을 진행하며 질병 없는 건강 및 풍요로운 삶을 목표로 하고 있음. 툴젠는 1999년에 설립되었으며 서울특별시 강서구에 본사를 두고 있습니다.